FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA

July 2, 2007

Dear Ms. Lalis:

The Food and Drug Administration (FDA) is pleased to cooperate with the European Commission (collectively “the Participants”), as part of cooperative law enforcement and cooperative regulatory activities, to facilitate the sharing of documents and/or information related to assuring the safety, quality, and efficacy, as appropriate, of cosmetics, including those OTC drugs which are defined as cosmetics in the EU. This information-sharing arrangement is intended, among other things, to help regulators on both sides to take informed decisions with regard to regulatory developments in their respective regions. We expect this cooperative activity to further enhance and strengthen communication between our respective organizations and further enhance public health promotion and protection and consumer protection in the European Union (EU) and the United States of America (USA). This arrangement should further the types of public health-related cooperative activities envisioned under the Guidelines on Regulatory Cooperation and Transparency developed by the EU and the USA under the Transatlantic Economic Partnership.

The types of information that may be shared include, but are not limited to, the following:

1. Advance drafts of laws, regulations, guidance documents, guidelines, procedures and other technical documents available to the individual Participants related to cosmetics.
2. Information on the process of validation and regulatory acceptance of alternative non-animal testing methods.
3. Information in the framework of European Rapid Alert System for non-food consumer products ( RAPEX).
4. Post-marketing data and information that could have an impact on the public health, such as vigilance data or information about impending regulatory actions.
5. Information on quality defect or product recalls of these products known by the FDA to have been manufactured or distributed in the EU, and vice versa.
6. Inspection reports and product sample test results describing the compliance of a cosmetic manufacturing facility with regulatory requirements.
7. Information related to Scientific Opinions.
8. Information on ongoing and emerging regulatory issues of health and safety in the field of cosmetics in the U.S. or the EU, such as nanotechnology.

Some of the information identified above may contain non-public information, such as confidential commercial information; trade secret information; personal privacy information; law enforcement information; or internal, pre-decisional information. FDA may only share these types of information as permitted by USA laws and FDA regulations. Among other things, FDA regulations require that a foreign government agency provide written assurance to FDA that it has the authority to protect non-public information from public disclosure and that it will not disclose such information. The European Commission has provided a statement to FDA affirming their authority and intent to maintain the confidentiality of non-public information provided by FDA to their officials or representatives under Article 4.1(a) of Regulation (EC) 1049/2001, which protects non-public information from further disclosure. The European Commission agrees that “confidential commercial information” includes information referred to in the US Freedom of Information Act, 5 U.S.C. § 552(b)(4), and in Regulation (EC) No. 1049/2001.

Similarly, FDA affirms that it has the authority to protect the confidentiality of the non-public information identified above under the Freedom of Information Act (FOIA) (5 U.S.C. § 552); the Trade Secrets Act (18 U.S.C. § 1905); section 301(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.§ 331(j)); and other applicable laws. Under the FOIA, the above non-public information shared by the European Commission with FDA is the type of information that can be withheld from public disclosure. FDA, therefore, in accordance with these statutes, consents not to disclose such non-public information provided to FDA by the European Commission absent the written permission of the sponsor/owner of the non-public information or written confirmation by the European Commission that the non-public information no longer has confidential status. The FDA agrees that “confidential commercial information” includes information referred to in the US Freedom of Information Act, 5 U.S.C. § 552(b)(4), and in Regulation (EC) No. 1049/2001.

Both Participants note that it is an essential element of this international arrangement on regulatory cooperation that confidential information emanating from the other Participant will be treated as such.

There also may be occasions when scientific experts from the Participants will visit each other’s agencies and will have access to non-public information. We have, therefore, enclosed an example of the Visitor Commitment Statement that visitors from the European Commission would be required to sign while visiting FDA if they are to have access to non-public information during the visit. We understand that FDA visitors to the European Commission would sign a similar commitment if, during their visit to the European Commission, they are to have access to non-public information.

[I doubt we want to notify/be notified of every FOIA request. Instead, use boilerplate paragraph as follows:] FDA will inform the European Commission promptly of any effort made by judicial or legislative mandate to obtain European Commission-provided non-public information from FDA. If such judicial or legislative mandate orders disclosure of European Commission-provided non-public information, FDA will take all appropriate legal measures in an effort to ensure that the information will be disclosed in a manner that protects the information from public disclosure.

Likewise, the European Commission will inform FDA promptly of any effort made by judicial or legislative mandate to obtain FDA-provided non-public information from the European Commission. If such judicial or legislative mandate orders disclosure of FDA-provided non-public information, the European Commission will take all appropriate legal measures in an effort to ensure that the information will be disclosed in a manner that protects the information from public disclosure.

The exchange of non-public information under this arrangement is reasonably necessary to facilitate cooperative law enforcement or cooperative regulatory activities between FDA, on the one hand, and the European Commission, on the other hand. All non-public information will be shared with the European Commission under this agreement in accordance with Title 21 of the Code of Federal Regulations § 20.89.

Each Participant will promptly inform the other of any changes to relevant laws, regulations, policies, or procedures that would affect the ability of the Participant to honor the understandings in this arrangement.

This cooperative arrangement is not intended to compromise any of the Participants' abilities to carry out their responsibilities.

This arrangement will commence July 2, 2007 for an initial period of five years, and remain in effect until July 2, 2012, during which time we will together assess its effectiveness on at least an annual basis and make any needed revisions.

This letter, together withyour letter on behalf of the European Commission, will constitute our mutual consent to implement these procedures.

We look forward to implementing these procedures that will allow for the sharing of information and to continuing our many cooperative activities to enhance the public health of our regions and to foster further the already beneficial and productive relationship between the European Commission and the FDA.

                                                          Sincerely,

                                                          -----S-----

                                                          Andrew C. von Eschenbach, M.D.
                                                          Commissioner of Food and Drugs
                                                          United Sates Food and Drug Administration

OIP Home Page

FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility

Office of International Programs